TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16270700

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat) treatment applied twice a year at six-month intervals in school settings among 854 adolescents.
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Supervised school-based fluoride mouth rinse (FMR) on the first three and last three school days during the school term (12 rinses/year) among 788 adolescents.
Number of subjects: 854

Group type: COMPARATOR
Intervention: Cessation of fluoride mouth rinse (FMR) for 3 years in a group of 60 adolescents with low caries prevalence.
Number of subjects: 854
Study: 11877694

Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound (CDU) scan
Number of subjects: 83

Group type: COMPARATOR
Intervention: Computed tomographic (CT) scan
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Doppler scan waveform pattern
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Spontaneous seal of T2ELs
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Overall prevalence of endoleaks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Incidence rate of endoleaks
Number of subjects: 83
Study: 10412990

Group type: EXPERIMENTAL
Intervention: Dysplastic hips (intervention group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Normal hips (control group)
Number of subjects: 66
Study: 7589414

Group type: EXPERIMENTAL
Intervention: Psychoeducational multiple family groups (MFGs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-family format
Number of subjects: 0

Group type: COMPARATOR
Intervention: MFGs without psychoeducation
Number of subjects: 0
Study: 2133939

Group type: EXPERIMENTAL
Intervention: Scavenged group (nitrous oxide with scavenging system)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonscavenged control (nitrous oxide without scavenging system)
Number of subjects: 20
Study: 7453037

Group type: EXPERIMENTAL
Intervention: 0.2% bromhexine eye drops
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.5% methyl cellulose eye drops
Number of subjects: 24
Study: 31335201

Group type: EXPERIMENTAL
Intervention: Insulin pump (CSII)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional self-monitoring of blood glucose (SMBG)
Number of subjects: 96
Study: 28934525

Group type: EXPERIMENTAL
Intervention: Nap condition (45-minute nap at 1300 h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No-Nap condition
Number of subjects: 19
Study: 27126957

Group type: EXPERIMENTAL
Intervention: Probiotic group consumed fermented milk with Bifidobacterium lactis HN019 (80 mL daily, 2.72 × 10^10 CFU) for 45 days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Probiotic group consumed fermented milk with Bifidobacterium lactis HN019
Number of subjects: 51
Study: 24483160

Group type: EXPERIMENTAL
Intervention: Automated glycemic control with adaptive meal-priming boluses
Number of subjects: 24

Group type: COMPARATOR
Intervention: Automated glycemic control without adaptive meal-priming boluses
Number of subjects: 24
Study: 22520791

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure and self-titration of antihypertensive medication
Number of subjects: 23
Study: 19643310

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 17166220

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 4782

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4782
Study: 16279581

Group type: EXPERIMENTAL
Intervention: Internet data capture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper-based data recording
Number of subjects: 0
Study: 11926889

Group type: EXPERIMENTAL
Intervention: Pramipexole, 0.5 mg 3 times per day with levodopa placebo (n = 42)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Carbidopa/levodopa, 25/100 mg 3 times per day with pramipexole placebo (n = 40)
Number of subjects: 82
Study: 10347342

Group type: EXPERIMENTAL
Intervention: Later intra-aortic balloon pump (IABP) deflation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional IABP timing
Number of subjects: 43
Study: 7753739

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin and heparin (adjunctive drugs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta blockers and angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0
Study: 2190864

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine 400 mg four times daily
Number of subjects: 0
Study: 7415650

Group type: EXPERIMENTAL
Intervention: 5000 units of subcutaneous heparin twice a day for a fortnight
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Heparinized group
Number of subjects: 150
Study: 29615077

Group type: EXPERIMENTAL
Intervention: SGI-110 (guadecitabine) combined with gemcitabine and cisplatin (GC) chemotherapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: GC chemotherapy (cisplatin 70 mg/m2, IV infusion, day 8; gemcitabine 1000 mg/m2, IV infusion, days 8 and 15)
Number of subjects: 56
Study: 26945890

Group type: EXPERIMENTAL
Intervention: BCG alone (247 patients)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: BCG + isoniazid (240 patients)
Number of subjects: 487

Group type: COMPARATOR
Intervention: BCG alone and BCG + isoniazid
Number of subjects: 487
Study: 23962460

Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (temperature 31 °C‐32 °C)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normothermic CPB (temperature >36 °C)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Hypothermic CPB
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normothermic CPB
Number of subjects: 140
Study: 22686495

Group type: EXPERIMENTAL
Intervention: Intranasal oxycodone (0, 14 & 28 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 20556471

Group type: EXPERIMENTAL
Intervention: 3‐monthly laser treatments with a StarLux 1,540‐nm fractional handpiece
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 10
Study: 18793361

Group type: EXPERIMENTAL
Intervention: Chemo-mechanical root canal preparation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Primary infections
Number of subjects: 40
Study: 15640294

Group type: EXPERIMENTAL
Intervention: Canadian Respiratory Illness and Flu Scale (CARIFS) data from a randomized controlled trial cohort
Number of subjects: 0
Study: 12766099

Group type: EXPERIMENTAL
Intervention: Oolong tea (1,500 ml) for 30 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water (control) for 30 days
Number of subjects: 20
Study: 10758942

Group type: EXPERIMENTAL
Intervention: Phentermine combined with fenfluramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phentermine alone
Number of subjects: 0
Study: 8930172

Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA) 30 mg/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA) 100 mg/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA) 15-50 mg/kg (second infusions)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 1732896

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micrograms/kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 44
Study: 6423317

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol (1 mg/actuation)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sodium cromoglycate via Spinhaler (20 mg)
Number of subjects: 25
Study: 30282077

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (SH) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 29590544

Group type: EXPERIMENTAL
Intervention: 3 months of CAPOX (capecitabine and oxaliplatin)
Number of subjects: 12834

Group type: EXPERIMENTAL
Intervention: 3 months of FOLFOX (fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 12834

Group type: EXPERIMENTAL
Intervention: 3 months of therapy (combined regimens)
Number of subjects: 12834

Group type: COMPARATOR
Intervention: 6 months of therapy (combined regimens)
Number of subjects: 12834
Study: 26509371

Group type: EXPERIMENTAL
Intervention: Vibram FiveFingers™ group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (traditional running shoes)
Number of subjects: 37
Study: 1449019

Group type: EXPERIMENTAL
Intervention: Urso plus colchicine (1 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Urso plus placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Urso alone (10-12 mg/kg) for 12 months
Number of subjects: 22
Study: 22695257

Group type: EXPERIMENTAL
Intervention: Auditory-based cognitive training (AT) plus social cognition training (SCT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo condition of non-specific computer games (CG)
Number of subjects: 22
Study: 20394080

Group type: EXPERIMENTAL
Intervention: Weighted analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unweighted analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed procedure
Number of subjects: 0
Study: 18713809

Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Massage (6 sessions)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Alexander technique (6 lessons)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Alexander technique (24 lessons)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Exercise prescription
Number of subjects: 579
Study: 16326671

Group type: EXPERIMENTAL
Intervention: Landiolol (0.25 to 0.5 mg.kg(‐1))
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Esmolol (1.0 mg.kg(‐1))
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Landiolol (0.5 mg.kg(‐1))
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both esmolol and landiolol
Number of subjects: 27
Study: 12432320

Group type: EXPERIMENTAL
Intervention: Early tracheostomy (ET) performed on postburn day (PBD) 4
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional therapy (CON) with tracheostomy performed on PBD 14 if necessary
Number of subjects: 44
Study: 10521736

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (20 mg every 4‐6 hours)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 74
Study: 8890875

Group type: COMPARATOR
Intervention: Pharmaceutical interventions
Number of subjects: 152
Study: 1683333

Group type: EXPERIMENTAL
Intervention: Zotepine (3 x 75 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol (3 x 4 mg)
Number of subjects: 0
Study: 6845096

Group type: EXPERIMENTAL
Intervention: Methohexitone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 100
Study: 31595970

Group type: EXPERIMENTAL
Intervention: Clinical assessment plus imaging (EUS and [18 F]FDG PET/CT)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard clinical assessment
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Imaging group (EUS and PET/CT)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 183
Study: 30373785

Group type: EXPERIMENTAL
Intervention: Usual care supplemented with an electronic patient-reported outcome measure (ePROM) intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study: 27794080

Group type: EXPERIMENTAL
Intervention: FreeO2 (variable oxygen flow)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oxygen at 2 L/min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Air at 2 L/min
Number of subjects: 16
Study: 24604881

Group type: EXPERIMENTAL
Intervention: Mild depressive symptoms (PHQ-9 score 5-9)
Number of subjects: 1418

Group type: EXPERIMENTAL
Intervention: Moderate to severe depressive symptoms (PHQ-9 score ≥10)
Number of subjects: 1418

Group type: COMPARATOR
Intervention: No depression (PHQ-9 <5)
Number of subjects: 1418
Study: 22367128

Group type: EXPERIMENTAL
Intervention: Spinal stabilization exercises (SSE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control exercise program
Number of subjects: 21
Study: 18952211

Group type: EXPERIMENTAL
Intervention: Olive oil breakfast
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Walnut breakfast
Number of subjects: 20

Group type: COMPARATOR
Intervention: Butter breakfast
Number of subjects: 20
Study: 21036889

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 4217
Study: 15827910

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) and medication therapy (MT) for the first 6 weeks, followed by MT only for the second 6 weeks.
Number of subjects: 68

Group type: COMPARATOR
Intervention: PT and MT for the second 6 weeks after receiving only MT for the first 6 weeks.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) and medication therapy (MT) for the second 6 weeks after receiving only MT for the first 6 weeks.
Number of subjects: 68
Study: 12350390

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) as adjunctive therapy, initiated at 0.5-1 mg/kg, titrated to a maximum of 12 mg/kg over a mean treatment period of 15.8 months (range 3-98 months).
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) as adjunctive therapy.
Number of subjects: 45
Study: 10611054

Group type: EXPERIMENTAL
Intervention: IFN-alfa-2b plus ribavirin for 24 or 48 weeks
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD, Caelyx(R))
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of PLD
Number of subjects: 1773
Study: 8952810

Group type: EXPERIMENTAL
Intervention: Indapamide 1.5 mg sustained-release form
Number of subjects: 690

Group type: COMPARATOR
Intervention: Indapamide 2.5 mg immediate-release form
Number of subjects: 690
Study: 1935254

Group type: EXPERIMENTAL
Intervention: 2 percent topical minoxidil
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 28
Study: 6282106

Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cellulose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pectin
Number of subjects: 6
Study: 29866165

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula therapy (HFNC)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 121
Study: 27371105

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25025854

Group type: EXPERIMENTAL
Intervention: Biphasic calcium sulfate (CS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biphasic calcium sulfate (CS) in combination with gamma‐radiated human mineralized allograft
Number of subjects: 10
Study: 22906960

Group type: EXPERIMENTAL
Intervention: Sudden weaning from NCPAP
Number of subjects: 56

Group type: COMPARATOR
Intervention: Gradual weaning from NCPAP
Number of subjects: 56
Study: 20801567

Group type: EXPERIMENTAL
Intervention: Each 2-kg/m(2) increase in BMI
Number of subjects: 652
Study: 18343262

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3-12 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3, 6, 9, 12, 15 mg/d)
Number of subjects: 0
Study: 15994396

Group type: EXPERIMENTAL
Intervention: Gastrostomy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nasogastric tube (Control)
Number of subjects: 41
Study: 12734745

Group type: EXPERIMENTAL
Intervention: Amlodipine suspension
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amlodipine tablets
Number of subjects: 20
Study: 10411029

Group type: EXPERIMENTAL
Intervention: Endoscopic implantation of self-expanding permanent endoluminal stents (Wallstent, Memotherm stent, Sinus stent)
Number of subjects: 13
Study: 8739863

Group type: EXPERIMENTAL
Intervention: Astemizole-D (10 mg astemizole and 240 mg pseudoephedrine)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Brompheniramine-D (12 mg brompheniramine and 50 mg phenylpropanolamine)
Number of subjects: 64
Study: 1911497

Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine and 100 micrograms fentanyl
Number of subjects: 108
Study: 6789205

Group type: EXPERIMENTAL
Intervention: Neonatal-intensive-care programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual interventions within neonatal intensive care
Number of subjects: 0
Study: 29521885

Group type: EXPERIMENTAL
Intervention: Phone-present with use encouraged
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Phone-present with use restricted
Number of subjects: 148

Group type: COMPARATOR
Intervention: No phone access
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cortisol responses
Number of subjects: 148
Study: 27626136

Group type: EXPERIMENTAL
Intervention: Active Monitoring
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1643
Study: 24438744

Group type: EXPERIMENTAL
Intervention: Glycopyrronium 50 μg once daily
Number of subjects: 657

Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily
Number of subjects: 657
Study: 22425041

Group type: EXPERIMENTAL
Intervention: Training on a urethrovesical model
Number of subjects: 28

Group type: COMPARATOR
Intervention: Basic laparoscopic suturing and knot tying on foam pads
Number of subjects: 28
Study: 21162825

Group type: EXPERIMENTAL
Intervention: Fasting capillary blood glucose cut-off value of 6.0 mmol/L for undiagnosed diabetes mellitus
Number of subjects: 3250

Group type: EXPERIMENTAL
Intervention: Fasting capillary blood glucose cut-off value of 5.7 mmol/L for impaired fasting glucose (IFG)
Number of subjects: 3250

Group type: EXPERIMENTAL
Intervention: Fasting capillary blood glucose cut-off value of 5.7 mmol/L for impaired glucose tolerance (IGT)
Number of subjects: 3250
Study: 17764477

Group type: EXPERIMENTAL
Intervention: Conventional cigarettes (FTC tar 11 mg; CC1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Conventional cigarettes (FTC tar 6 mg; CC2)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cigarette switch (FTC tar 1 mg; CC3)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Stop smoking
Number of subjects: 3
Study: 15564721

Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 antibody), administered in up to 4 treatment cycles, possibly in combination with corticosteroid, cyclophosphamide, and/or methotrexate.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 antibody)
Number of subjects: 40
Study: 11953726

Group type: EXPERIMENTAL
Intervention: Cephalexin (80-100 mg/kg/day)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 9876550

Group type: EXPERIMENTAL
Intervention: Metoprolol (generic preparation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Betaloc (innovator product)
Number of subjects: 12
Study: 8747407

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 160
Study: 2233115

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nifedipine 10 mg three times daily
Number of subjects: 40
Study: 401521

Group type: EXPERIMENTAL
Intervention: Ticarcillin alone
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus gentamicin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Gentamicin alone
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 71
Study: 31678947

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Exercise 150 min/week + Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Exercise 150 min/week + Liraglutide 3.0 mg/day
Number of subjects: 200
Study: 28143414

Group type: EXPERIMENTAL
Intervention: Toothbrushing plus 0.12% chlorhexidine gel
Number of subjects: 213

Group type: COMPARATOR
Intervention: Chlorhexidine solution 0.12% without toothbrushing
Number of subjects: 213
Study: 26291873

Group type: EXPERIMENTAL
Intervention: Soothing liver and regulating mind group
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Acupoint shallow puncturing group
Number of subjects: 163

Group type: COMPARATOR
Intervention: Non-acupoint shallow puncturing group
Number of subjects: 163
Study: 19262364

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no paroxetine)
Number of subjects: 0
Study: 21208101

Group type: EXPERIMENTAL
Intervention: Iniparib plus gemcitabine and carboplatin
Number of subjects: 123

Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin (control)
Number of subjects: 123
Study: 18172769

Group type: EXPERIMENTAL
Intervention: Drug Court with usual community‐based treatment (DC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DC with Multisystemic Therapy (DC/MST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DC/MST enhanced with Contingency Management (DC/MST/CM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Family Court with usual community‐based treatment (FC)
Number of subjects: 0
Study: 17926489

Group type: EXPERIMENTAL
Intervention: Chronotherapy with monocinque
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Complex treatment with monocinque and melatonin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional therapy with monocinque
Number of subjects: 65
Study: 15226683

Group type: EXPERIMENTAL
Intervention: Diacerein
Number of subjects: 0
Study: 11137278

Group type: EXPERIMENTAL
Intervention: Standard referral with an incentive
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Staff escort from detoxification to aftercare with an incentive
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard referral
Number of subjects: 196